Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 36 for:    AMINOCAPROIC ACID

Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02238288
Recruitment Status : Unknown
Verified September 2014 by Grupo de Estudos Multicentricos em Onco-Hematologia.
Recruitment status was:  Enrolling by invitation
First Posted : September 12, 2014
Last Update Posted : September 12, 2014
Sponsor:
Collaborator:
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Information provided by (Responsible Party):
Grupo de Estudos Multicentricos em Onco-Hematologia

Brief Summary:
Patients using anticoagulants present an increased risk of bleeding when subjected to oral surgery. Suspending or reducing the oral anticoagulant dose to perform invasive procedures, may result in thromboembolic events, putting patients health in risk. Recent studies advocate the dental surgery treatment without suspending the anticoagulant therapy, since the values of the international normalized ratio (INR) are in acceptable therapeutic levels and local measurements are taken for the hemostasis control. The aim of this study is to compare the effectiveness use of intra-alveolar epsilon amino caproic acid (EACA) associated to daily rinses with the drug, with routine post-surgical procedures, to control the post-exodontic bleeding in anticoagulated patients. Patients will be referred by the anticoagulation clinic of the Clementino Fraga Filho University Hospital. Once the study criteria is met patients will be randomly allocated into two groups and subsequently subjected to clinical and periodontal examination, radiographic examination and pre-operative periodontal therapy. Laboratory tests (partial thromboplastic time, prothrombin time, international normalized ratio and platelet count) will be held on the day of the extraction. Patients in group 1 ( EACA ) will receive a paste composed of 01 macerated EACA tablet (500 mg), mixed with 0.9% saline solution in the alveolar socket, and routine post-operative care. Additionally, patients will perform oral rinses three times a day, on the first two post-operative days, with a solution from the macerated EACA 500mg tablet diluted in 2 spoons of filtered water. Patients allocated in group 2 (control) will receive routine post-operative care. Classification of immediate bleeding will be held by the professional, on the day of the surgery, immediately after the suture and twenty minutes later and the delayed bleeding, recorded by the patient through a daily questionnaire. The Statistical Package for the Social Sciences (SPSS)© (IBM, Chicago, USA) 20.0 is used as the database and the Chi-square, Kruskal-Wallis and Mann-Whitney tests will be applied to statistical analysis of the results.The study was approved by the ethical and research committee of the Clementino Fraga Filho University Hospital . All patients will sign a free consent and informed term.

Condition or disease Intervention/treatment Phase
Oral Hemorrhage Drug: Aminocaproic acid Other: Routine dental care Drug: lidocaine and epinephrine Drug: Paracetamol Phase 4

Detailed Description:

All patients will be submitted to clinical and radiographic examination. Once selected, patients will receive hygiene instruction and will be submitted to full mouth scaling one week before the procedure with an ultrasonic device (CavitronR - Dentsply). The random allocation of patients will obey the order obtained in the computerized program Allocation 1.0 Software© (Isfahan, Iran, 2004). All patients should have the prothrombin time (PT) and INR, active thromboplastin partial time (aTPT) and platelet counts tests on the day of surgery. Patients who present INR< 2.0 e > 4 will be assessed by the medical team about the possibility of change in the dose of medication to the surgical procedure. Patients with predisposing heart conditions the bacterial endocarditis will receive antibiotic prophylaxis as recommendations from American Association of Cardiology (AHA) of 2007. All extraction procedures will be performed by non-traumatic conventional surgical techniques, under local anesthesia (2% lidocaine and epinephrine 1: 100,000). Just one extraction will be performed in each surgical procedure, by the same surgeon. All patients will receive digital compression of socket with sterile gauze for 5 minutes (Chompret `s manoeuver) and suture with non-resorbable wire, silk 3.0 type . Everyone will receive the base analgesic prescription Paracetamol 750 mg (Tylenol© - Johnson & Johnson), 01 tablet every 6 hours, by oral administration, for control of postoperative pain. Patients are divided into two groups:

Group 1 (EACA) - patients will receive the intra-alveolar application of a 500 mg tablet of the epsilon-amino caproic acid (EACA - Ipsilon® - Nikko Brazil, RJ) crushed in 0.9% saline. Additionally, they will be instructed to rinse with 500mg EACA tablets macerated and diluted in 2 tablespoons of water three times a day, in the two days after the extraction.

Group 2 (control) - patients will receive routine postoperative care.

Classification of Bleeding will be performed by the professional on the day of surgery at two times: one time (immediately after extraction) and time 2 (after 20 minutes). The bleeding will be classified as follows:

  • No bleeding
  • Light bleeding - blood in saliva
  • Moderate Bleeding - bleeding controlled with local measures
  • Severe Bleeding - when surgical intervention is required

Late bleeding will be recorded by the patient through daily questionnaire. The bleeding will be classified as follows:

  • No bleeding
  • Blood stained saliva
  • Bleeding that stopped after compression bandage and ice pack for 20 minutes
  • Bleeding stopped only after professional intervention

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Randomized Clinical Trial to Verify the Effectiveness of Topical Aminocaproic Acid in the Prevention of Post-exodontic Bleeding in Patients on Anticoagulants
Study Start Date : December 2013
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : July 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: aminocaproic acid
Crushed tablets inserted in the dental socket post-extraction
Drug: Aminocaproic acid
Crushed tablet in the dental socket
Other Name: Ipsilon©

Drug: lidocaine and epinephrine
2%

Drug: Paracetamol
750 mg

Routine care after dental extraction
Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
Other: Routine dental care
Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
Other Name: Routine procedures after dental extractions

Drug: lidocaine and epinephrine
2%

Drug: Paracetamol
750 mg




Primary Outcome Measures :
  1. bleeding post-exodontic [ Time Frame: up to twenty minutes ]
    • No bleeding
    • Bleeding Light - blood in saliva
    • Moderate Bleeding - bleeding controlled with local measures
    • Severe Bleeding - when required surgical intervention and / or hospitalization



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients over 18 years of age, use of warfarin sodium with or without anti-platelet aggregation, indicating simple extractions whose INR values are between 2.0 and 4.0 and that consent to participate in the study.

Exclusion Criteria:

  • Patients with platelet count < 50,000 / mm3 Pregnant women or lactating Patients with hypersensitivity to the components of EACA. Patients with coagulopathies Patients who have impacted teeth, ankylosed or root morphological alterations that may complicate the procedure Patients who fail to submit laboratory and radiographic examinations necessary for the surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02238288


Locations
Layout table for location information
Brazil
Clementino Fraga Filho University Hospital
Rio de Janeiro, RJ, Brazil, 21864-440
Sponsors and Collaborators
Grupo de Estudos Multicentricos em Onco-Hematologia
Rio de Janeiro State Research Supporting Foundation (FAPERJ)

Layout table for additonal information
Responsible Party: Grupo de Estudos Multicentricos em Onco-Hematologia
ClinicalTrials.gov Identifier: NCT02238288     History of Changes
Other Study ID Numbers: AEAC2014
First Posted: September 12, 2014    Key Record Dates
Last Update Posted: September 12, 2014
Last Verified: September 2014
Keywords provided by Grupo de Estudos Multicentricos em Onco-Hematologia:
anticoagulation
extraction
epsilon amino caproic
Additional relevant MeSH terms:
Layout table for MeSH terms
Aminocaproic Acid
Oral Hemorrhage
Hemorrhage
Pathologic Processes
Mouth Diseases
Stomatognathic Diseases
Oral Manifestations
Signs and Symptoms
Epinephrine
Anticoagulants
Physiological Effects of Drugs
Peripheral Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Mydriatics
Sympathomimetics
Vasoconstrictor Agents
Antifibrinolytic Agents
Fibrin Modulating Agents
Hemostatics
Coagulants